[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"post-stroke-cognitive-impairment-psci\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:post-stroke-cognitive-impairment-psci":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,46,70,95,130],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100634991","high-frequency-repetitive-transcranial-magnetic-stimulation-for-cognitive-improvement-in-patients-with-post-stroke-cognitive-impairment-100634991",false,"NCT07546877","High-Frequency Repetitive Transcranial Magnetic Stimulation for Cognitive Improvement in Patients With Post-Stroke Cognitive Impairment","Efficacy of High-Frequency Repetitive Transcranial Magnetic Stimulation in Patients With Post-Stroke Cognitive Impairment: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Meets the diagnostic criteria for stroke as stipulated in the \"Guidelines for the Prevention and Treatment of Stroke in China (2021 Edition)\", and the initial stroke diagnosis is confirmed by cranial CT or MRI examination, and is confirmed as the initial onset;\n2. The disease course is 1-12 months;\n3. Has cognitive impairment (MoCA \\\u003C 26 points, education years ≤ 12 years, add 1 point to the score result);\n4. Age 35-75 years old, gender not limited;\n5. Stable vital signs, no progressive neurological symptoms;\n6. No severe aphasia, visual or auditory impairment, and able to complete the research protocol;\n7. Not using antidepressant drugs simultaneously;\n8. If using cognitive-improving drugs (such as donepezil, memantine), it should last for at least 3 weeks or more, and no dose adjustment will be made during the enrollment period;\n9. Voluntarily participate and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Has a history of brain tumors, brain trauma, epilepsy or mental disorders;\n2. Had cognitive impairment before the stroke;\n3. Underwent craniotomy or had a skull defect;\n4. Had implanted metal or electronic devices (such as cardiac pacemakers, cochlear implants, deep brain stimulators, aneurysm clips, internal fixation devices after ventriculoperitoneal shunt surgery, etc.);\n5. Has other serious diseases that may affect the study;\n6. Pregnant women","ALL","35 Years","75 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","To clarify the clinical efficacy of high-frequency rTMS on patients with post-stroke cognitive impairment, fNIRS and EEG techniques were used to observe the changes in brain functional activities of patients with post-stroke cognitive impairment after rTMS treatment, and to clarify the neuroregulatory effect of rTMS on patients with post-stroke cognitive impairment.",[27,28,29],"Post-Stroke Cognitive Impairment (PSCI)","Repetitive Transcranial Magnetic Stimulation (rTMS)","Stroke",[31,32],"randomized controlled trials","double blind","RECRUITING","2026-04-21",{"date":36,"type":37},"2026-04-23","ACTUAL",{"date":39,"type":21},"2026-04-01",{"date":41,"type":21},"2027-07-01",{"name":43,"class":44},"Qilu Hospital of Shandong University","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":45},"100627718","artificial-intelligence-based-cognitive-training-in-patients-with-stroke-100627718","NCT07452276","Artificial Intelligence-Based Cognitive Training in Patients With Stroke","Effect of Artificial Intelligence-Based Training on Cognitive Functions in Patients With Stroke","AICoRe-Stroke","Inclusion Criteria:\n\n* Patient's age will range from 45- 60 years.\n\n  * Diagnosis of stroke in the chronic stage (≥3 months post-onset).\n  * Presence of cognitive impairment confirmed by a Montreal Cognitive Assessment (MoCA) score ≤ 26.\n  * Medically stable and able to follow instructions.\n  * patients with memory deficits following stroke\n\nExclusion Criteria:\n\n\\- Patients will be excluded if they have:\n\n* Severe visual, hearing, or speech impairments prevent participation.\n* History of other neurological or psychiatric disorders.\n* Unstable cardiovascular or systemic disease.\n* Severe depression (Beck Depression Inventory \\> 29).","45 Years","60 Years",{"count":20,"type":21},[24],"This study would answer the following question:Does AI application-based training improve cognitive function in Patients with Stroke?\n\nThe aims of this study:\n\nTo investigate the efficacy of AI application-based training on cognitive function in stroke patients.",[27,29,60],"Artifical Intelligence","2026-03-01",{"date":63,"type":37},"2026-03-05",{"date":65,"type":37},"2026-01-01",{"date":67,"type":21},"2026-06-06",{"name":69,"class":44},"Omima Alaa Eldin Hussein",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":81,"conditions":82,"keywords":83,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":5},"100608935","electroacupuncture-treatment-for-post-stroke-cognitive-impairment-100608935","NCT07208019","Electroacupuncture Treatment for Post-stroke Cognitive Impairment","Study on the Key Technology of Acupoint Modulation-based Brain Electric Field Therapy for the Treatment of Post-stroke Cognitive Impairment","Inclusion criteria\n\n* According to the Western diagnostic criteria for vascular cognitive impairment outlined in the \"Chinese Guidelines for the Diagnosis and Treatment of Vascular Cognitive Impairment (2024 Edition)\" developed by the Vascular Cognitive Impairment Branch of the Chinese Stroke Society.\n* Meets the traditional Chinese medicine diagnostic criteria for vascular cognitive impairment in the \"Guidelines for Traditional Chinese Medicine Diagnosis and Treatment of Vascular Mild Cognitive Impairment (2024)\";\n* The Mini Mental State Examination (MMSE) score ranges from 12-24, while the Montreal Cognitive Assessment (MoCA) score is below 24; Having cognitive impairment but not reaching the level of severe dementia; The National Institutes of Health Stroke Scale (NIHSS) score is ≤ 8 points; The Early Dementia Screening Scale (Ascertain Dementia 8, AD-8) score is less than 2 points;\n* Age between 35-80 years old;\n* Have basic communication skills, with Mandarin as the main language (communication language is sufficient), and have at least one stable caregiver;\n* Sign the informed consent form.\n\nExclusion criteria\n\n* Merge serious primary chronic diseases such as heart, liver, kidney, endocrine system, and hematopoietic system, as well as severe cardiovascular and cerebrovascular diseases;\n* Skin diseases or scar constitution such as herpes and ulceration are easy to appear on the body surface, which is not suitable for acupuncture and moxibustion treatment;\n* Not suitable for repetitive MRI examinations, such as claustrophobia, arterial aneurysm embolization, etc;\n* Patients with cognitive impairment or other severe neurological or mental disorders prior to the onset of this illness, and unstable control;\n* Patients identified by other clinical trial personnel as unsuitable for this study;\n* Participated in clinical research on related diseases in the past 3 months;","80 Years",{"count":79,"type":21},340,[24],"Stroke is a global public health issue, and it has become a leading cause of death and disability in China. With the rapid aging of the Chinese population, its incidence rate is continuously rising. According to the \"China Stroke Prevention and Treatment Report (2023)\", on average, one person experiences a new or recurrent stroke every 10 seconds in China, and one person dies from stroke every 28 seconds. Currently, there are 4 million new stroke cases in China each year, with 12.42 million individuals aged 40 and above currently suffering from stroke, and the affected population is showing a trend of younger onset. Among survivors, approximately 75% suffer from residual disabilities, and 40% have severe disabilities. Consequently, patient families will experience significant economic losses and physical and psychological pain.\n\nPost-Stroke Cognitive Impairment (PSCI) is a common complication of stroke, where patients develop cognitive impairment within six months after the stroke event that meets the diagnostic criteria for cognitive impairment. PSCI is defined as a clinical phenomenon secondary to stroke events, with cognitive decline as its core characteristic. Such impairments encompass cognitive dysfunction caused by various stroke types and are one of the main determinants of functional dependency in post-stroke survivors. The prevalence of PSCI within six months is approximately 30% to 50%, with 10% progressing to dementia. Additionally, PSCI patients face a high risk of death, with up to 61% dying within five years. Countries worldwide have launched targeted guidelines, calling for increased attention and investment in this major complication. However, current treatments for PSCI are still limited to secondary prevention measures for stroke and drugs for treating Alzheimer's disease-like conditions, all lacking high-level clinical evidence. Therefore, effective treatments are urgently needed to improve patient outcomes.\n\nPSCI is a dynamically evolving process, with individual differences in its occurrence time, influencing factors, clinical manifestations, and recovery prognosis. The unique diagnostic system of traditional Chinese medicine may assist in analyzing the disease progression of PSCI. The study of the patterns of syndrome evolution can help explain and provide reference for treatment. Currently, there are no specific drugs for treating PSCI, and relevant drug treatments lack high-level evidence. In recent years, with the development of imaging, artificial intelligence, and electromagnetic physics, non-pharmacological therapies have gradually become one of the research hotspots in the field of PSCI. It is worth noting that non-invasive brain stimulation, represented by transcranial electrical stimulation, is a therapy that directly acts on the brain lesions of PSCI and is often used in combination with acupoint stimulation to achieve better therapeutic effects. Meanwhile, acupuncture and moxibustion therapy has demonstrated good efficacy and safety in the prevention and treatment of PSCI. Multiple clinical studies suggest that electroacupuncture therapy can improve cognitive impairment in patients with PSCI and enhance their quality of life. Furthermore, electroacupuncture therapy can also provide targeted treatment for patients through syndrome differentiation and treatment, compensating for the limitations of Western medicine drug therapy.\n\nThis study aims to investigate the evolution patterns of syndromes in post-stroke cognitive impairment (PSCI). Simultaneously, through the standardization of multidimensional and multimodal data related to PSCI patients, we will conduct a multicenter, large-sample clinical randomized controlled trial of electroacupuncture intervention for PSCI using a multimodal artificial intelligence big data model. The goal is to establish a characteristic technology for the diagnosis and treatment of PSCI in traditional Chinese medicine (TCM) that is suitable for promotion, and to establish clinical diagnosis and treatment pathways and standard specifications for diseases where TCM has advantages. This will facilitate the establishment of an efficacy evaluation system for PSCI based on TCM syndrome diagnosis and evolution patterns, realize a precise diagnosis and treatment model combining traditional Chinese and Western medicine for PSCI, and improve patients' overall efficacy and quality of life.",[27],[29,84,85],"PSCI","Post-stroke cognitive impairment","2025-12-09",{"date":88,"type":37},"2025-12-17",{"date":90,"type":37},"2025-10-05",{"date":92,"type":21},"2027-03-30",{"name":94,"class":44},"Ruijie Ma",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":102,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":22,"phases":105,"briefSummary":106,"conditions":107,"keywords":112,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":45},"100602565","immersive-virtual-reality-in-cognitive-rehabilitation-of-patients-with-post-stroke-cognitive-impairment-100602565","NCT07125170","Immersive Virtual Reality in Cognitive Rehabilitation of Patients With Post-Stroke Cognitive Impairment","Immersive Virtual Reality in Cognitive Rehabilitation of Patients With Post-Stroke Cognitive Impairment: A Pilot Study at the Department of Physical Medicine and Rehabilitation, Clinical Hospital of the University of Chile","Inclusion Criteria:\n\n* Patients over 18 years of age\n* Patients with a cerebrovascular accident of any etiology with less than 3 months of progression\n* Patients with mild to moderate cognitive impairment post-stroke (impairment in at least one cognitive domain)\n* MoCA score of less than 24 points\n* Referred for cognitive rehabilitation at the Occupational Therapy Unit of HCUCH\n\nExclusion Criteria:\n\n* Patients with refractive errors that prevent the use of the headset\n* Patients with any type of aphasia that prevents the administration of the MoCA test\n* Patients with severe psychiatric disorders (presence of psychotic symptoms or derealization)\n* Patients with severe motor impairments (lack of trunk control or global strength of both upper limbs \\\u003C M3)","18 Years",{"count":104,"type":21},20,[24],"This pilot study aims to evaluate the feasibility of implementing immersive virtual reality (VR) in cognitive rehabilitation for adults with post-stroke cognitive impairment receiving outpatient therapy. Participants will use a head-mounted display and interactive software to engage in gamified cognitive exercises that simulate memory, attention, and executive function tasks. The intervention consists of 10 sessions, delivered two to three times per week over a period of approximately four weeks. The study will assess multiple feasibility indicators, including the recruitment rate based on eligibility criteria, the safety and tolerability of VR sessions for participants, and the usability and satisfaction reported by occupational therapists administering the intervention. Additionally, exploratory outcomes include changes in global cognition and specific cognitive domains, as well as self-reported quality of life. Adverse effects related to VR use will be tracked. This pilot study will help inform the design and implementation of future, larger-scale clinical trials.",[29,27,108,109,110,111],"Cognitive Dysfunction","Virtual Reality Therapy","Virtual Reality Cognitive Training","Cognitive Rehabilitation",[113,114,115,116,117,118,119,120],"virtual reality","Cognitive rehabilitation","Immersive Therapy","Meta Quest 3","Kinesix XR","Occupational Therapy","Montreal Cognitive Assessment (MoCA)","Simulator Sickness Questionnaire (SSQ)","2025-08-08",{"date":123,"type":37},"2025-08-15",{"date":125,"type":37},"2025-08-06",{"date":127,"type":21},"2026-05-01",{"name":129,"class":44},"University of Chile",{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":22,"phases":139,"briefSummary":141,"conditions":142,"keywords":144,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":45},"100514258","phase-3-effect-of-butyphthalide-on-cognitive-level-change-after-cerebral-vascular-event-a-randomized-control-trial-be-clever-100514258","NCT05976152","Effect of Butyphthalide on Cognitive Level Change After Cerebral Vascular Event-a Randomized Control Trial (Be-CLEVER)","Be-CLEVER","Inclusion Criteria:\n\nFirst stage:\n\n* Acute ischemic stroke (AIS) symptom onset within 14 days Signs and symptoms consistent with the diagnosis of an acute ischemic stroke by CT\u002FMRI.\n* Age \\>= 60 years，\n* Baseline NIHSS 3-18.\n* Patient can complete questionnaire survey, physical examination, cranial MRI and other medical examinations\n* Patient\u002Flegally authorized representative has signed the Informed Consent Form\n\nSecond stage:\n\n* Patient with stage I diagnosis of PSCI.\n* Patient can complete questionnaire survey, physical examination, cranial MRI and other medical examinations.\n* Patient\u002Flegally authorized representative has signed the Informed Consent Form\n\nExclusion Criteria:\n\nFirst stage:\n\n* Patients who had been diagnosed with dementia prior to stroke\n* Other related factors affecting cognitive function: central nervous system infection, neurodegenerative diseases, trauma, poisoning, intracranial space occupying lesions, metabolic diseases, etc.\n* Other serious central nervous system diseases: Parkinson's disease, epilepsy, multiple sclerosis, motor neurone disease, immune-related encephalomyelopathy, etc.\n* Serious mental illness: anxiety disorder, depression, delirium, schizophrenia, bipolar disorder, mental retardation, which is diagnosed or controlled by medication.\n* Uncorrectable visual and hearing impairments and inability to complete neuropsychological tests\n* Severe liver and kidney dysfunction\n* The presence of a malignant tumor or other serious\u002Flife-threatening disease that could cause the subject's death within 12 months.\n* Current known alcohol or illicit drug abuse or dependence\n* Patients undergoing thrombectomy, thrombolysis, carotid endarterectomy, or other surgical procedures during the acute infarction.\n* Using cholinesterase inhibitors, N-methyl-D-aspartate (NMDA) receptor antagonists, or Sodium oligomannate (GV-971).\n* Allergic to any component of butylphthalein\n* Pregnancy or lactation, have the possibility of becoming pregnant, and who plan to become pregnant\n* Participants in other interventional clinical trials\n* MRI contraindications (e.g., claustrophobia, hypersensitivity to contrast media, etc.)\n\nSecond stage:\n\n* During the first phase of follow-up, participants' compliance was poor, with study medication compliance less than 80% or greater than 120%; Follow-up was less than 24 weeks or did not complete the follow-up within the follow-up window..\n* Recurrent stroke in the first stage",{"count":138,"type":21},3200,[140],"PHASE3","Post-stroke cognitive impairment (PSCI) refers to a clinical syndrome characterized by cognitive impairment that occurs after a stroke event and persists for at least 24 weeks. Due to the early recovery of conditions such as delirium and transient cognitive impairment after stroke, the diagnosis of PSCI often requires cognitive assessment at 12 to 24 weeks post-stroke to determine the severity of cognitive impairment. It can be classified according to the severity of cognitive impairment as post-stroke cognitive impairment no dementia (PSCIND) and post-stroke dementia (PSD). Recent large international cohort studies have reported an incidence rate of PSCI ranging from 24% to 53.4%, and patients with PSCI have a significantly higher mortality rate compared to those without cognitive impairment. Guidelines such as American Heart Association\u002FAmerican Society of Anesthesiologists (AHA\u002FASA) and the Chinese \"Expert Consensus on the Management of Post-Stroke Cognitive Impairment\" propose integrating cognitive impairment and stroke intervention strategies. Early comprehensive intervention and treatment for high-risk individuals after stroke, aiming to delay or prevent the progression from PSCIND to PSD, are the primary goals in the current treatment of PSCI. However, there is currently a lack of large randomized controlled trials (RCTs) for PSCI, and research is still needed to determine whether cognitive-enhancing drugs can reduce the risk of PSCI occurrence and improve outcomes and prognosis for PSCI patients. A randomized, double-blind, multicenter clinical study involving 281 non-dementia vascular cognitive impairment (VCI) patients showed that the overall cognitive scores of patients treated with donepezil for 24 weeks significantly improved compared to the placebo group.\n\nThe aim of this study is to evaluate the effectiveness of donepezil in the treatment of post-stroke cognitive impairment. It will be a multicenter, randomized, double-blind, placebo-controlled trial with a 48-week treatment duration. The study will observe the difference in PSCI incidence rate between the donepezil treatment group and the conventional stroke treatment group at 24 weeks and evaluate the improvement in post-stroke cognitive impairment after 6 months of donepezil treatment compared to conventional treatment.\n\nThis study will be conducted in two stages: the first stage (0-24 weeks) aims to assess whether donepezil can reduce the risk of PSCI occurrence and will be a multicenter, randomized, double-blind, placebo-controlled study. The second stage (24-48 weeks) aims to evaluate whether donepezil can improve the prognosis of PSCI patients and will also be a multicenter, randomized, double-blind, placebo-controlled study.",[29,143],"Post-stroke Cognitive Impairment (PSCI)",[145,84,146],"stroke","Butylphthalide","2024-04-12",{"date":149,"type":37},"2024-04-15",{"date":151,"type":21},"2024-04",{"date":153,"type":21},"2026-12",{"name":155,"class":44},"Fudan University"]